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Sir,
In two cross-over randomized controlled trials (RCTs)
published in the Journal of Headache and Pain, frova-
triptan 2.5 mg had a similar efﬁcacy to that of rizatriptan
10 mg [1] and almotriptan 12.5 mg [2]. In both RCTs
preference, the primary efﬁcacy measure was quite com-
parable as were pain free and headache relief after 2 h, and
sustained pain free for 2–48 h [1, 2]. In contrast, in a
systematic review of triptans [3n] the mean therapeutic
gain (active minus placebo) for headache relief at 2 h was
19% (95% CI 16–22%) for frovatriptan 2.5 mg, whereas it
was 33% (95% CI 31–35%) for sumatriptan 100 mg, 34%
(95% CI 30–37%) for zolmitriptan 2.5 mg, 36% (95% CI
32–39%) for rizatriptan 10 mg, and 27% (95% CI 20–33%)
for almotriptan 12.5 mg. The superiority of sumatriptan
100 mg versus frovatriptan 2.5 mg was conﬁrmed in a not
fully published large (n = 1196) RCT in which the head-
ache relief rates were 47 and 37%, respectively [4, 5]. The
recurrences rates for frovatriptan (25%) and sumatriptan
(31%) were similar.
Migraine patients in these RCTs [3, 4, 6] waited until
the headache was moderate or severe whereas patients in
the cross-over RCT were instructed to treat the migraine
attack as early as possible [1, 2]. Data on headache severity
at the time of treatment were not reported in the papers on
these two RCTs [1, 2]; a peculiar omission in papers on
acute migraine RCTs. In addition, patients not responding
to triptans were excluded and the patients in the two cross-
over trials were, therefore, most likely less afﬂicted by
migraine than the ones participating in the parallel group
RCTs in which such patients were not excluded. The most
likely reason for the comparable efﬁcacy of frovatriptan
and zolmitriptan [7], rizatriptan [1] and almotriptan [2]i n
these cross-over RCTs is, however, the very early use of
test treatment.
In conclusion, frovatriptan is for moderate and severe
headache not the triptan of ﬁrst choice (therapeutic gain for
frovatriptan is only 19 vs. 27–36% for other triptans, see
above). However, if the migraine patients are able to treat
their attacks very early, and have not demonstrated inad-
equate response to other triptans, then frovatriptan is most
likely a good alternative to other triptans.
Yours sincerely
Peer Carsten Tfelt-Hansen
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